AI Article Synopsis
- A patient with advanced pancreatic cancer received a single infusion of genetically modified T cells designed to target a specific mutation (KRAS G12D) in the tumor.
- The treatment led to a significant reduction in tumor size, showing a 72% overall partial response, which continued for at least six months.
- Over time, the modified T cells remained active, making up over 2% of the patient's circulating T cells six months post-treatment, indicating effective long-term engagement against the cancer.
Article Abstract
A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×10 autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02-restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors. The patient had regression of visceral metastases (overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1); the response was ongoing at 6 months. The engineered T cells constituted more than 2% of all the circulating peripheral-blood T cells 6 months after the cell transfer. In this patient, TCR gene therapy targeting the KRAS G12D driver mutation mediated the objective regression of metastatic pancreatic cancer. (Funded by the Providence Portland Medical Foundation.).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531755 | PMC |
| http://dx.doi.org/10.1056/NEJMoa2119662 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!